BetMakers FY26 slides: EBITDA surges 205% amid margin gains
BetMakers FY26 slides: EBITDA surges 205% amid margin gains
Profit by knowlytics
BetMakers FY26 slides: EBITDA surges 205% amid margin gains
Earnings call transcript: Adheris Health posts steep FY2026 revenue decline in H2 2026
Lumino Industries will finalize its ₹700-crore IPO allotment today after a subscription of 124.02 times. Successful bidders will receive notifications regarding their allotment status. The shares are expected to debut on September 3.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —Lumax AutoTechnologies, Vijaya Diagnostic Centre, Tamilnad Mercantile Bank, EPL, and Sansera Engineering.
BetMakers FY26 slides: EBITDA surges 205% as margins near target
Sophie Cunningham is back in the spotlight after an old podcast clip resurfaced, with the Indiana Fever guard describing the WNBA as a surprisingly wild and close-knit environment. Cunningham claimed NBA players “don’t even come close” to the conversations happening among WNBA players and admitted some remarks are too crazy to repeat. Another old interview…
The Tamil romantic comedy-drama ‘Hi’ experienced a substantial box office decline on its first Monday. The film collected an estimated Rs 91 lakhs net in India on its fourth day. This represents a significant 60.4% drop from the previous day’s earnings. The movie’s total India net collection has now reached Rs 6.61 crore. Monday brought…
The French spirits maker is trimming mid-to-senior management roles to sharpen focus on high-margin categories, even as strong sales in India buck a global slowdown.
Duane Davis was convicted of orchestrating Tupac Shakur’s 1996 murder. The jury reached its verdict after nearly thirty years since the shooting occurred. Prosecutors presented multiple statements where Davis admitted responsibility for the fatal incident. His defense argued he was lying, but no witness corroborated this claim. Davis now faces a potential life sentence for…
Chief executive and vice chairman Rajeev Nannapaneni lays bare the changing face of global pharma, explaining why Indian generics firms are scouting for new opportunities.